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ABSTRACT 
 
BACKGROUND:   
The goal of postnatal total parenteral nutrition (TPN) in premature neonates (PT) 
is to mimic the intrauterine environment of the fetus. Micronutrients are essential 
for optimal development. Although carnitine is present in human breast milk and 
is supplemented in infant formula, very preterm infants primarily receive 
parenteral nutrition, often devoid of carnitine, shortly after birth. Carnitine plays a 
critical role in cellular and mitochondrial metabolism.  Preterm infants are 
deficient in carnitine as it is transferred from the placenta to the fetus during late 
pregnancy. Previously, our group surveyed US neonatologists in 2001 regarding 
carnitine supplementation practices and found that the majority were not fully 
familiar with the implications of carnitine deficiency and only 28% of preterm 
neonates on TPN were receiving carnitine.  Since this study, recent research has 
emphasized the impact of carnitine on early weight gain and its neuroprotective 
effects.   
 
OBJECTIVE:  
 vi 
To determine current TPN carnitine supplementation practices in fasting preterm 
neonates (< 32 wks and < 1,500g) by conducting a national survey of board-
certified neonatologists.   
 
DESIGN/METHODS:   
The survey was distributed via electronic-mail to physicians through a listserv of 
neonatologists operated by the American Academy of Pediatrics Section on 
Perinatal Pediatrics.  The survey assessed physicians’, institutions’ and patients' 
characteristics; as well as physicians' knowledge, beliefs, and practices regarding 
carnitine screening and supplementation in preterm neonates.   
 
RESULTS: 
Characteristics of Respondents: We received 490 responses to our survey, out of 
2900 members who were invited; thus the response rate was 17%. 97% of the 
respondents were in active practice (>20 hours/week; >8 weeks/year in NICU 
settings); 88% were attendings, with >10 years of experience (63%), serving an 
average of 29.5 weeks/year. Characteristics of Institutions: 92% level III NICU, 
averaging 678 admissions/year, from states that had implemented expanded 
newborn screens (66%). Characteristics of NICU newborns: 74% were GA <32 
weeks, BWT <1500g; >1:4 were exclusively on TPN for >72 hours (62%). 
Physician’s Knowledge: 67% of neonatologists correctly identified carnitine as 
present in breast milk and 21% were aware of placental secretion. Physician’s 
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Beliefs: 72% believed that carnitine deficiency was not a rare event in PT, and 
could have serious consequences (60%); 44% believed that carnitine could be 
neuroprotective. Physician’s Practices: 226 responders had diagnosed carnitine 
deficiency in PT; 5% routinely screened for deficiency and 40% routinely used 
carnitine supplemented TPN in PT.  
  
CONCLUSIONS:   
Survey response rates in our range have been shown to provide accurate 
measurements. Two-thirds of respondents recognized carnitine presence in 
breast milk, but 4/5 did not identify placental secretion. The majority also did not 
list the correct dose of carnitine that should be administered to preterm neonates. 
Neonatologists believed that carnitine deficiency was not rare in PT, with 
potential serious consequences. Almost all believed that carnitine could be 
neuroprotective (98%). The percentage of respondents who reported routinely 
supplementing carnitine increased from 30% in 2000 to 40% in 2012. Years of 
training or level of NICU did not affect the physician’s evaluation of carnitine 
deficiency, supplementation practice or dosage prescribed. There are still many 
providers who do not routinely supplement carnitine.  Yet, few respondents 
routinely screened for deficiency (5%) or used supplemented TPN (40%), leaving 
most PT still at risk for unrecognized carnitine deficiency and its potentially 
serious consequences.  
 viii 
TABLE OF CONTENTS 
 
Title           i 
Reader’s Approval Page        ii   
Dedications          iii 
Acknowledgements         iv 
Abstract           v 
Table of Contents         viii 
List of Tables         xi 
List of Figures         xiii 
List of Abbreviations         xiv 
Introduction          1 
Prematurity Outcomes 
 Role of Carnitine 
 Cellular Models 
 Animal Models and Neuroprotection 
 Studies on Human Subjects 
 Carnitine Deficiency in Preterm Infants 
 Controversies Regarding Carnitine Supplementation 
 Carnitine’s Unreported Benefits 
Carnitine Supplementation Practices 
 Objective 
 Hypothesis 
 ix 
Methods          19 
 Survey Development 
 IRB 
 Survey Distribution  
Statistical Analysis 
Results          21 
 Survey Response 
 Respondents Characteristics  
 Hospital’s Carnitine Screening and Dosing Practices 
 NICU Population Characteristics 
 Carnitine Supplementation Practices 
 Physicians’ Beliefs on Carnitine Supplementation 
 Comparison to Last Survey 
 Selected Response Comparison  
Discussion           30 
 Our Findings 
Individualized Nutrition and Carnitine Recommendations 
 Sample Representativeness 
 Carnitine and Its Side Effects  
Controversies Regarding Carnitine Supplementation Dosage  
Limitations 
 Conclusion 
 x 
Future Directions 
Appendix          38 
References          47 
Vita           53 
 xi 
LIST OF TABLES 
 
 
Table Title Page  
1 Studies of L-carnitine supplementation in parenteral and 
enteral nutrition 
11 
2 Comparison of first 50 responses and total responses to 
selected survey questions.  
21 
3 Respondent Characteristics 22 
4 Hospital’s Carnitine Screening and Dosing Practices 23 
5 NICU Population Characteristics 24 
6 Carnitine Supplementation Practices 25 
7 Physicians’ Beliefs on Carnitine Supplementation 26 
8 Comparison of 2001 and 2012 Survey Respondent 
Demographics  
27 
9 Selected Responses Compared by Level of NICU and 
Years of Experience 
28 
10 Full Respondent Characteristics 42 
11 Full Hospital’s Carnitine Screening and Dosing Practices  42 
12 Full NICU Population Characteristics 43 
13 Full Physicians’ Beliefs on Carnitine Supplementation 44 
14 Full Comparison of 2001 and 2012 Survey Respondent 44 
 xii 
Demographics  
15 Full Comparison of Selected Responses from Level I, II, III 
NICUs 
45 
16 Full Comparison of Selected Responses by Years of 
Experience 
46 
 
 xiii 
LIST OF FIGURES 
 
Figure  Title Page  
1 Cellular level events that occur during hypoxic ischemic 
brain injury in the neonate. 
2 
2 Fatty Acid transport across the mitochondrial membrane 5 
3 Comparison of 2001 and 2012 Survey Results 27 
4 Theoretical Dosage of Carnitine to Administer 28 
5 Comparison of Carnitine Dosage and Years of Experience 29 
 
 
 xiv 
ABBREVIATIONS  
 
 
ATP   Adenosine Tri-Phosphate 
BW   birth weight 
CoA   co-enzyme A 
JNK   c-Jun N-terminal kinase 
ELBW   Extremely Low Birth Weight 
GSK-3b  Glycogen Synthase Kinase 3 
Hrk   Harakiri 
IQ   Intelligence Quotient 
IV   Intravenous 
LBW   Low Birth Weight 
MCADD  Medium Chain Acyl Dehydrogenase Deficiency 
NICU   Neonatal Intensive Care Unit 
NO   Nitric Oxide 
PDA   Patent Ductus Arteriosus 
PP2A   Protein Phosphatase 2A 
PT   Preterm 
RCT   Randomized Clinical Trial 
TPN   Total Parenteral Nutrition 
URL   Uniform Resource Locator 
VLBW   Very Low Birth Weight 
 1 
INTRODUCTION 
Prematurity Outcomes:  
Every year, one out of every eight babies in the United States are born 
premature (“CDC Features - National Prematurity Awareness Month,” n.d.).  
Premature birth, also known as preterm birth, is defined as birth at least 3 weeks 
before the baby’s due date (“CDC Features - National Prematurity Awareness 
Month,” n.d.). Prematurity is a known risk factor for developmental problems such 
as intellectual disabilities and cerebral palsy (“CDC Features - National 
Prematurity Awareness Month,” n.d.).   
Developmental outcomes in preterm infants are determined in part by the 
presence or absence of brain injury and brain growth (Wood, Marlow, Costeloe, 
Gibson, & Wilkinson, 2000).  The newborn brain is susceptible to damage from 
lack of oxygen and blood flow, also known as hypoxic-ischemic injury.  
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Figure 1: Cellular level events that occur during hypoxic ischemic brain injury in the neonate. 
(Vannucci & Perlman, 1997) (Shalak & Perlman, 2004)  
As shown in Figure 1, the depletion of oxygen results in a switch to 
anaerobic metabolism that results in many cellular events leading to cell death. 
Going clockwise, cellular energy failure occurs because the products of 
glycolysis, NADH and FADH, cannot keep up with the energy demands of the 
cell. Furthermore, lactate and H+ ions produced by anaerobic metabolism create 
acidotic conditions within the cell. Transcellular pumping fails, which leads to 
intracellular accumulation of Na+, Ca2+, Cl- and water resulting in the membranes 
to depolarize and release glutamate, an excitatory neurotransmitter (Shalak & 
Perlman, 2004).  
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Glutamate activates receptors in the cell surface resulting in an influx of 
Na+ and Ca2+ into the post synaptic neurons (Shalak & Perlman, 2004). Free 
fatty acids accumulate from increased membrane phospholipid turnover, 
resulting in lipid peroxidation by oxygen-free-radicals (Shalak & Perlman, 2004). 
Ca2+ ions accumulate and induce the production of nitric oxide (NO) which 
diffuses to susceptible cells nearby (Shalak & Perlman, 2004). This cascade of 
events disrupts important parts of the cell resulting in cell death (Shalak & 
Perlman, 2004). Hypoxic-ischemic injuries can result in cerebral palsy, mental 
retardation, learning difficulties, other disabilities and even death (Bryce, Boschi-
Pinto, Shibuya, & Black, 2005).  
Brain growth occurs very rapidly in late fetal life; as a result, preterm 
infants can experience reduced cortical growth which predicts lower 
neurocognitive function (Lawn, Shibuya, & Stein, 2005). Furthermore, weight 
gain and head circumference growth during the early neonatal period has been 
associated with a lower incidence of cerebral palsy, subnormal mental 
development index and neurodevelopment impairment (Rathbone et al., 2011). 
Increased energy supply from intensive early nutritional support is associated 
with increased weight gain, head circumference growth and improving overall 
growth (Franz et al., 2009). 
In fact, less than optimal nutrition during the critical period of early brain 
development (last trimester to age 2) may have long term effects on cognitive 
function (Lucas, Morley, & Cole, 1998a). Lucas et al. (1998) conducted a 
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randomized trial where preterm infants were fed standard formula or formula 
supplemented with breast milk. They found that infants who received enriched 
formula had higher verbal IQ scores and a lower incidence of cerebral palsy than 
infants who were fed standard formula (Lucas, Morley, & Cole, 1998b). Breast 
milk contains factors including immunoglobulins, vitamins that are absorbed 
better, oligosaccharides to promote intestinal health, and its composition is 
adjusted regularly by the body to better meet the baby’s needs (Lucas et al., 
1998a). In 2012, it was reported that lipid intake during the first two weeks of life 
was associated with improved neurological development at one year of age. 
(Eleni dit Trolli, Kermorvant-Duchemin, Huon, Bremond-Gignac, & Lapillonne, 
2012)   
Role of Carnitine:  
As previously mentioned, the overproduction of free radicals can cause 
oxidative stress which can cause cell death (Perrone, Salvi, Bellieni, & 
Buonocore, 2007). Antioxidants eliminate free radicals and are thought to play an 
important role in protecting infants from this form of brain damage (Perrone et al., 
2007).  Carnitine is an antioxidant that enhances energy production and protects 
cells against the deleterious effects of acyl CoAs (Arenas, Rubio, Martín, & 
Campos, 1998).  
Carnitine transports long-chain fatty acids into the mitochondrial matrix so 
they can be broken down to produce energy, via beta-oxidation (Jogl, Hsiao, & 
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Tong, 2004).  Since fatty acids cannot permeate the mitochondrial membrane, 
the carnitine system acts as a shuttle (Jogl et al., 2004).  
 
Figure 2: Fatty acid transport across the mitochondrial membrane via the Carnitine System. 
Adapted from "Biochemistry," by Jeremy M. Berg, John L. Tymoczko, and Lubert Stryer, 2001, 
New York: W.H. Freeman and Company. Copyright 2001 by the WH Freeman Company. 
Adapted with permission.  
 
As shown in Figure 2, carnitine acyltransferase I, which is located on the 
mitochondrial outer membrane, catalyzes the exchange of acyl groups between 
Carnitine and CoA (Jogl et al., 2004). Next, acylcarnitine crosses the inner 
mitochondrial membrane in a reaction catalyzed by a specific 
carnitine/acylcarnitine translocase (Jogl et al., 2004). Next, Carnitine 
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acyltransferase II disrupts the acyl-carnitine complex by rebinding the fatty acid 
to CoA (Jogl et al., 2004). Carnitine diffuses back across the membrane using 
the carnitine-acylcarnitine translocase (Jogl et al., 2004).   
While acting as a shuttle, carnitine maintains free coenzyme-A for 
metabolic pathways; protects cells against accumulation of toxic acyl-coenzyme-
A compounds; and stores metabolic energy (Crill & Helms, 2007).  
Cellular Models:  
Carnitine is known to influence important mitochondrial proteins, such as 
carnitine acyltransferase, in energy production and is believed to play a 
neuroprotective role in some pathological conditions (Picconi et al., 2006). Acetyl 
carnitine in the brain can improve mitochondrial function, be incorporated into 
lipids, regulate genes and proteins and enhance cholinergic transmission (Jones, 
McDonald, & Borum, 2010). In order for an effect to be neuroprotective, there 
must be an active choline uptake system and activation of M2 muscarinic 
receptors (Picconi et al., 2006). Picconi et al. (2006) observed the 
neuroprotective action of carnitine when administered before in-vitro ischemia in 
newborn rat neurons.(Picconi et al., 2006)  
Animal Models and Neuroprotection:  
Similarly, in newborn rats exposed to hypoxic-ischemic injury, treatment 
with carnitine reduced neurologic injury and no protective effect was observed 
when carnitine was administered after injury (Wainwright, Mannix, Brown, & 
Stumpf, 2003).   
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Literature examining the effects of carnitine supplementation in models of 
neurodegenerative diseases show great promise as well. Alzheimer’s disease is 
characterized by neurofibrillary degeneration caused by tau phosphorylation 
which is regulated by protein phosphatase 2A (PP2A) (Jiang et al., 2011). Yin et 
al. (2010) reported that carnitine administration can reverse tau 
hyperphosphorylation and memory deficits induced by protein phosphatase 2A 
inhibition.  
GSK-3β in a protein kinase that is thought to be involved in the buildup of 
Amyloid-β deposits and the formation of neurofibrillary tangles (Jiang et al., 
2011). While examining the role of GSK-3β inhibition in Alzheimer’s disease, it 
was found that feeding rats carnitine for two weeks can improve spatial memory 
retention impairment and attenuate tau hyperphosphorylation (Jiang et al., 2011). 
Also, they found that carnitine enhanced the expression of memory associated 
proteins which suggests that carnitine could improve spatial memory deficits by 
inhibiting tau hyperphosphorylation (Jiang et al., 2011).  
Parkinson’s disease is believed to be partially caused by the degeneration 
of dopaminergic neurons due to oxidative stress (Zaitone, Abo-Elmatty, & 
Shaalan, 2012). Based on the hypothesis that neurodegeneration may be caused 
by mitochondrial dysfunction and oxidative injury, it would be useful to consider 
metabolic modifiers in early intervention and alternative treatments (Zaitone et 
al., 2012). Treatment with carnitine has been shown to improve motor 
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performance and reduce the level of lipid peroxides in rat models of Parkinson’s 
disease (Zaitone et al., 2012).  
Studies on Human Subjects:  
The effects of carnitine have been studied in neurologic disorders in 
human subjects.    Rett syndrome is a rare, inherited disease that mostly afflicts 
girls (De Felice et al., 2012). It causes developmental and nervous system 
problems and its symptoms are loss of speech, loss of purposeful hand 
movements and compulsive hand movements (De Felice et al., 2012). 
Unfortunately, there is no cure for Rett syndrome but the symptoms can be 
treated (Ellaway et al., 1999). In a randomized controlled trial of carnitine 
supplementation in patients with Rett syndrome, an improvement in hand 
movement was observed for a higher proportion of girls on L-carnitine than 
placebo (Ellaway et al., 1999).  
Diabetic neuropathy is a disorder where nerves are damaged due to high 
blood sugar levels in diabetic patients (De Grandis & Minardi, 2002). When 
patients were randomized to treatment with carnitine or placebo, an improvement 
in nerve conduction velocity and amplitude was observed and after a 1 year 
treatment period, a reduction in pain was observed as well (De Grandis & 
Minardi, 2002). Thus, it seems as though carnitine plays a very important role in 
neuroprotection.  
Carnitine Deficiency in Preterm Infants:  
During the third trimester of pregnancy, carnitine is transferred from the 
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placenta to the fetus and stored in the heart, muscle and liver (Melegh, 1990).  
Also, carnitine is found in human breast milk in an adequate concentration of 60-
70 nmol/ml. (Penn, Dolderer, & Schmidt-Sommerfeld, 1987)  Carnitine has been 
demonstrated to be an important micronutrient for the neonate and hence has 
been added to most enteral infant formulas (Jiang et al., 2011). While 
macronutrient composition of preterm infant formula may vary, total fat, total 
energy and total protein content are reported to be within the same range (Klein, 
2002). However, extremely low birth weight (ELBW) infants routinely receive total 
parenteral nutrition (TPN) which lacks carnitine supplementation (Melegh, 1990). 
In addition, preterm infants are born with low stores of carnitine as placental 
transfer did not occur and they have a reduce capacity to synthesize carnitine 
(Melegh, 1990). After birth, carnitine levels of very preterm babies decline more 
rapidly than infants who were born at later gestational ages; hence, preterm 
infants are at increased risk of carnitine deficiency (Melegh, 1990). These factors 
along with the fact that most preterm babies receive parenteral nutrition devoid of 
carnitine for prolonged periods makes it important for exogenous sources of 
carnitine to be administered to prevent deficiency in the preterm infant.   
In children, carnitine deficiency has been associated with impaired fatty 
acid oxidation, as expected, and failure to thrive as well as multi-organ failure 
(Winter et al., 1987).  
The National Institute of Child Health and Human Development Workshop 
states that “optimal nutrition of extremely low birthweight (ELBW) infants should 
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meet the unique and changing nutrient requirements of these infants and support 
growth that mimics normal fetal growth.” (Hay et al., 1999) According to the 
institute, this goal is not met very often and as mentioned earlier, inadequate 
early nutrition can have a strongly negative impact on long-term outcome and 
produce deficits in behavior, learning, and memory (Hay et al., 1999). In their 
workshop summary, the role of many nutritional requirements was evaluated. 
However, carnitine was not included in the discussion.  
Controversies Regarding Carnitine Supplementation:  
Lack of standardized dosing, caloric, protein intake and inconsistent 
measures of growth have resulted in studies showing varying results of carnitine 
supplementation. There is variability regarding the importance of carnitine as an 
essential micronutrient in the fasting neonate. 
Helms et al. (1990) conducted a study to determine whether intravenous 
(IV) administration of carnitine would improve nitrogen and carnitine balance and 
they found that neonates receiving carnitine treatment had greater 
concentrations of carnitine, greater nitrogen and weight gain (Helms, Mauer, 
Hay, Christensen, & Storm, 1990). They conclude that carnitine supplementation 
may have enhanced the neonates ability to use exogenous fat for energy thus 
increasing growth modestly (Helms et al., 1990).  
In 1995, Bonner studied the effects of parenteral L-carnitine 
supplementation on fat metabolism, nutrient intake and carnitine concentration in 
very low birth weight (VLBW) infants (Bonner, DeBrie, Hug, Landrigan, & Taylor, 
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1995). They found that the carnitine supplemented group had greater weight gain 
than the control group during the first two weeks of life (Bonner et al., 1995). 
They conclude that parenteral administration of carnitine alleviates the neonate’s 
carnitine deficiency (Bonner et al., 1995).  
However, a double blind placebo controlled randomized trial was 
conducted on preterm infants and the researchers found that there was no 
significant difference in growth rate between the two groups (Shortland et al., 
1998). They did not observe any increases in weight, length, skin fold thickness 
and head circumference (Shortland et al., 1998).   Similarly. a review looking at 
randomized clinical trials of carnitine supplementation in parenterally fed 
neonates was conducted in the UK in 2000 and they found that carnitine 
supplementation did not have any effect on weight gain, lipid utilization or 
ketogenesis (Cairns & Stalker, 2000).  
Since 2001, there have been many advances in understanding the role of 
carnitine in the preterm infant. Table 1 summarizes some key studies that 
demonstrate the impact of early carnitine supplementation on growth and 
development. Of the six randomized clinical trials in the table below, four 
demonstrated a lack of effect of carnitine on neonatal growth and variable dosing 
regimes were observed which may have contributed to the lack of effect. 
Table 1 
Studies of L-carnitine supplementation in parenteral and enteral nutrition 
Study Desi
gn 
Patient 
Characteristi
Intervention Dosage Results 
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cs 
(O’Donnell
, Finer, 
Rich, 
Barshop, 
& 
Barrington
, 2002) 
RCT 44 preterm 
neonates were 
enrolled by the 
2
nd
 day of life 
Infants received 
parenteral nutrition 
and were randomized 
to carnitine or 
placebo 
30 
mg/kg/day 
There was no 
increase in time 
to regain birth 
weight or reach 
enteral feeds. 
Storm et 
al. 2003 
RCT 30 preterm 
neonates were 
enrolled by 6
th
 
day of life 
Infants received 
parenteral nutrition 
and were randomized 
to carnitine or 
placebo 
124 
mmol/kg/d
ay 
There was a 
shortened time 
to regain 
birthweight in 
carnitine 
supplemented 
neonates  
(Whitfield, 
Smith, 
Sollohub, 
Sweetman
, & Roe, 
2003) 
RCT 64 preterm 
neonates 
enrolled by 4
th
 
day of life.  
Infants received 
parenteral nutrition 
and were randomly 
assigned IV infusions 
of L-carnitine or no 
supplementation  
15 
mg/kg/day 
No growth 
advantage was 
observed as 
exogenous 
sources and/or 
endogenous 
synthesis was 
enough for 
steady rise in 
carnitine levels.  
(Pande, 
Brion, 
Campbell, 
Gayle, & 
Esteban-
Cruciani, 
2005) 
RCT 63 preterm 
neonates were 
enrolled by the 
3
rd
 day of life 
Infants received 
parenteral nutrition 
and were randomly 
assigned carnitine 
supplementation  
10 
mg/kg/day 
No difference in 
daily weight 
gain, time to 
regain BW, or 
length of stay. 
(Crill et al., 
2006) 
RCT 29 preterm 
neonates were 
enrolled by 4
th
 
day of life 
Infants received 
parenteral nutrition 
and were randomized 
to carnitine 
supplementation or 
placebo 
20 
mg/kg/day 
Carnitine 
supplemented 
neonates 
regained 
birthweight more 
rapidly than 
placebo  
(Seong, 
Cho, Park, 
& Cha, 
2010) 
RCT 25 Low birth 
weight (LBW) 
neonates 
enrolled by 7th 
day of life  
Starting 5
th
 day of life, 
infants received 
parenteral nutrition 
(pre-mature infant 
formula with 
carnitine) with or 
without carnitine 
supplementation or 
placebo 
10 
mg/kg/day 
Carnitine 
supplementation 
did not increase 
growth rate 
(height, weight, 
head 
circumference) 
but it did 
normalize and/or 
enhance lipid 
metabolism in 
premature 
infants in Korea.  
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Previously, our group conducted a randomized clinical trial to investigate 
the effect of L-carnitine supplementation on weight gain in very preterm 
infants(Pande et al., 2005).  There was no difference observed in weight gain at 
hospital discharge; however, there was decreased weight loss during 
supplementation period (data previously not reported) (Pande et al., 2005).  
Similarly, Crill et al. (2006) conducted a randomized, double blind, 
controlled study where neonates were administered placebo or carnitine. They 
found that the carnitine-supplemented neonates regained birthweight more 
rapidly than control neonates (Crill et al., 2006). They concluded that carnitine 
had a positive effect on catch-up growth and it may improve periodic breathing in 
premature neonates(Crill et al., 2006).    
The positive effect on catch-up growth in premature infants has been 
related to neurodevelopmental outcomes (Crill et al., 2006). However, the effect 
of carnitine supplementation on neurodevelopmental outcomes remains 
unexplored. Our group postulates that carnitine supplementation in preterm 
infants may protect against neuronal damage and enhance brain growth, and 
result in improved neurodevelopmental outcomes in childhood.   
Carnitine’s Unreported Benefits:  
There are unreported benefits of carnitine supplementation that our group 
previously observed but did not publish because they were not the initial 
objectives of the study. Infants treated with carnitine had a significantly lower rate 
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of proven infection than control infants, a finding which may be related to 
previous work investigating the impact of carnitine on lymphocyte counts in 
immunocompromised patients (Moretti et al., 1998). Previously, carnitine 
supplementation was found to significantly increase CD4 counts and positively 
increase CD8 counts (Moretti et al., 1998). Moreover, there was a decrease in 
the frequency of apoptotic CD4 and CD8 lymphocytes and a decline in the levels 
of ceramide, an endogenous mediator of apoptosis that also enhances HIV-1 
replication (Moretti et al., 1998). Another unreported finding was the rate of 
hearing screen failure was markedly reduced in carnitine-treated infants.  This 
finding is congruent with previous work by our group, which showed that carnitine 
is protective against ototoxicity. In newborn guinea pigs exposed to gentamicin, a 
treatment for infections due to Gram negative bacteria and an ototoxic agent, 
carnitine prevents changes in hearing threshold and cochlear damage (Kalinec et 
al., 2005). With respect to the molecular mechanisms, carnitine prevents 
gentamicin induced apoptosis and upregulation of Harakiri (Hrk), a pro-apoptotic 
factor by the c-Jun N-terminal kinase (JNK) which is normally inhibited by Hrk 
(Kalinec et al., 2005).  
Carnitine Supplementation Practices: 
The need for carnitine supplementation and the effect of supplementation 
on preterm infants remains controversial and requires further study. Our group 
believes that the importance of carnitine supplementation in preterm infants 
should not be overlooked, as there is growing evidence in the literature that 
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carnitine is necessary to “support growth that mimics normal fetal growth.” (Hay 
et al., 1999).    
In 2001, our group conducted a national survey of carnitine 
supplementation practices in neonatal intensive care units (NICU). We conducted 
a national electronic survey of board-certified neonatologists in order to 
determine current TPN carnitine supplementation practices in fasting preterm 
neonates (<32 weeks and <1,500 gm). They found that carnitine was routinely 
supplemented in approximately one-third of the units(Esteban-Cruciani, 2001).  
The majority of neonatologists surveyed were not fully familiar with the 
implications of carnitine deficiency and did not routinely provide carnitine 
supplementation (Esteban-Cruciani, 2001). Specifically, 34% of neonatologists 
identified that carnitine deficiency was “not rare” in fasting preterm infants, while 
42% were not sure (Esteban-Cruciani, 2001). 52% identified carnitine as being 
"present in breast milk", while only 12% recognized carnitine as being "secreted 
by the placenta" (Esteban-Cruciani, 2001).  34% believed that deficiency could 
have serious consequences in neonates (Esteban-Cruciani, 2001).  Only 2% of 
preterm neonates were screened for carnitine deficiency, and only 28% routinely 
received carnitine-supplemented TPN (Esteban-Cruciani, 2001).   
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OBJECTIVE: 
The goal of this study was to determine current TPN carnitine 
supplementation practices in fasting preterm neonates (< 32 wks and < 1,500g) 
by conducting a national survey of board-certified neonatologists.  
Particular attention was paid to:  
 Physician’s knowledge 
 Physician’s beliefs 
 Physician’s practices  
Responses obtained from neonatologists were categorized by: (1) years of 
experience and (2) level of NICU and compared to see if there is a difference in 
carnitine supplementation and knowledge.  
Personal Objectives:  
I undertook this study for two reasons- I wanted to be a part of a clinical 
trial and I wanted to give back to the Children’s Hospital at Montefiore where my 
sister had open heart surgery 18 years ago. The doctors I worked with are 
currently enrolling patients in a clinical trial examining the neuroprotective effects 
of carnitine supplementation in preterm neonates. Prior to starting the study, the 
doctors wanted to survey neonatologists and their supplementation practices.  
Ultimately, from this study I wanted to, and successfully did, expand my 
clinical skills. I learned about infant and child development by shadowing a 
pediatrician in her various clinics. By attending Infant Toddler and Adolescent 
team conferences, I learned about different conditions and complications in child 
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development. Being a part of the research meetings taught me about the IRB 
process required when conducting a clinical trial. Writing this thesis allowed me 
to search literature on survey analysis, NICU practices and carnitine in neonates. 
I contributed to this randomized clinical trial by informative brochures for parents, 
creating and maintained a database with the data recorded from the NICU. 
Lastly, I collected and analyzed survey responses and performed thorough 
statistical analyses to assess supplementation practices.  
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HYPOTHESIS: 
Based on the results of the previous survey, I hypothesize that most 
neonatologists do not routinely supplement carnitine; do not screen for carnitine 
and might not be aware of carnitine’s role in preterm nutrition.  
The respondents from Level III NICU’s will be more likely to use carnitine 
supplemented TPN and the average dose they would administer to a preterm 
infant will be closer to the recommended average dose. The respondents with 
more years of experience will be more likely to use carnitine supplemented TPN 
and will be more knowledgeable regarding carnitine dosing.  
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METHODS 
Survey Development:  
Based on questions from the survey sent in 2001 and established 
knowledge on carnitine, a questionnaire was developed. The questions covered 
the following domains: respondent’s characteristics (5 items), hospital 
characteristics (8), physician’s practice (4), carnitine knowledge and practices 
(9).  
In the Respondent’s Characteristics section, there were questions with 
fixed responses asking the physician’s position in Neonatology, years in practice 
and level of NICU. 
 In the Hospital Characteristics Section, there were two fixed response 
questions, three opinion questions, and three questions asking the respondents 
to enter answers. A 5-point Likert scale was used in opinion questions asking 
respondents to select from the following options, Strongly Disagree, Disagree, 
Neutral, Agree and Strongly Agree.  
In the Physician’s Practice section, there were three fixed response 
questions and one asking respondents to enter their own answer.  
Lastly, in the Carnitine Knowledge section, all the items posed were 
opinion questions where respondents were asked to select their response from a 
5-point Likert scale.  
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IRB:  
The survey was exempted by the Institutional Review Board at Montefiore 
since it did not record email or URL addresses to link the responses with the 
respondents.  
Survey Distribution:  
The survey consists of 25 items and was administered through the 
website SurveyMonkey (www.surveymonkey.com). The survey was distributed 
via electronic-mail to physicians through a listserv of neonatologists operated by 
the American Academy of Pediatrics Section on Perinatal Pediatrics.  The survey 
was sent twice (two weeks apart) to participants.  
 
Statistical Analysis: 
Survey data was compiled in spreadsheet through SurveyMonkey and then 
exported to Microsoft Excel (Microsoft Corporation, Redmond, WA) for analysis.  
Responses were tabulated and analyzed for all respondents.   Responses to 
individual questions were evaluated by using standard summary statistics such 
as the mean (± standard deviation) or frequency, depending on the response 
format for the question. The “Filter” Option in Microsoft Excel was used to sort 
the answers of neonatologists with more than 10 years; 5-10 years; and less than 
5 years of experience as well as filter the responses of Level I, II and III NICU 
neonatologists.   
 21 
RESULTS 
Survey Response:  
The survey was sent to 2900 members of the Perinatal Section of the American 
Academy of Pediatrics. 490 respondents started the survey and 360 completed 
the survey, thus making the response rate 16.9%. The characteristics of the 
respondents’ practice are reported in Table 2. Most of the respondents were 
attending neonatologists with more than 10 years of experience who spent at 
least 8 weeks/year in the NICU.  
While the survey may have had a response rate of 17%, a comparison 
between the demographics first 50 responses and total responses reveals that 
there is no significant difference between the first 50 respondents and total 
respondents with regards to the mean number of weeks spent in the NICU/year 
(p=0.1534) and the number of NICU admissions/year (p=0.3905). Also, chi 
squared test results revealed that there is no significant difference between the 
first 50 respondents and all the responses with respect to proportion of 
attendings, fellows and nurse practitioners (p=0.8251); and level of NICU they 
practice in (p=0.4648). However, there was a significant difference in the years of 
experience between the first 50 responses and all the responses (p=0.0253).  
Table 2.  
 
Comparison of first 50 responses and total responses to selected survey 
questions.  
 
 First 50 responses All responses 
Attendings: 
Fellows:  
82% 
20% 
87.5% 
10.1% 
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NP/PA: 2% 2.4% 
<2 years: 
2-5 years: 
>5-10 years: 
>10 years: 
2% 
12% 
20% 
62% 
9.3% 
13.7% 
13.5% 
63.4% 
Mean number of 
weeks in NICU/year: 
27.06 ± 15.09 weeks/year 29.49 ± 16.64 weeks/year 
Level I: 
Level II: 
Level III: 
2% 
4% 
90% 
1.3% 
6.9% 
91.8% 
Number of NICU 
admissions/year: 
649.07 ± 337.09 
admissions/year 
677.51 ± 719.48 
admissions/year 
%preterm: 47.2 ± 46.81% 74.35% ± 366.3 % 
 
Respondent’s Characteristics:  
Most respondents were attendings in active practice with more than 10 years of 
experience and spending more than half of the year in the NICU (Table 3).  
Table 3  
 
Respondent Characteristics.  
 
Survey Question Response Percent of 
Respondents 
Are you currently on active practice 
(on average >20 hours/week)? 
(N=474) 
Yes 
No  
97.25 
2.75 
Do you currently spend at least 8 
weeks/year in a neonatal intensive 
care unit (NICU)? (N=473) 
Yes 
No 
96.62 
3.38 
 
Please indicate your current 
position in Neonatology: (N=465) 
 
Attending 
Fellow  
NP/PA 
Nutrition Manager/Dietician 
Professor 
Retired 
Pediatrician Level I 
Nursery 
87.5 
10.1 
2.4 
1.0 
0.2 
0.2 
0.2 
Since completion of your residency >10 years 63.4 
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training, how many years have you 
spent in Neonatology? (N=473) 
>5-10 years 
2-5 years 
<2 years 
13.5 
13.7 
9.3 
How many weeks/year are you 
responsible for direct patient 
care/supervision in NICU? (N=470)  
Mean: 29.49 ± 16.64 weeks/year 
Median: 26 weeks 
 
 
Hospital’s Carnitine Screening and Dosing Practice 
Characteristics of the hospital are reported in Table 4. The respondents mostly 
practiced in states with an expanded screen for carnitine deficiency (66%) and 
these screens were easily available and inexpensive at their hospitals. The 
hospitals that most respondents practice in do not have an established dose of 
carnitine (63.5%). 
Table 4 
Hospital’s Carnitine Screening and Dosing Practice 
Survey Question Response Percent of 
Respondents 
Does your state have an expanded 
screen for carnitine deficiency? (N=355) 
Yes 
I don’t know 
No 
66.9 
24.8 
9.6 
Screening for deficiency is not easily 
available (N=344) 
Disagree 41.6 
Screening for deficiency is expensive 
(N=344) 
Disagree 26.4 
Hospital has an established dose of 
carnitine. (N=341)  
Agree 21.5 
 
 
 
NICU Population Characteristics 
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The characteristics of the patient population are reported in Table 5. Most of the 
respondents (92%) spent their time in a Level III NICU. There was an average of 
677.51 admissions in 2011 and most hospitals reported that 74.35% of those 
admissions were preterm infants.  More than 1 in 4 were exclusively on TPN for 
>72 hours (62%).  
Table 5 
 
NICU Population Characteristics  
 
Survey Question Response Percent of 
Respondents 
Please choose the level of NICU in 
which you spend most of your time. 
(N=473) 
Level I 
Level II 
Level III 
1.3 
6.9 
91.8 
How many newborn infants were 
hospitalized in your NICU during 
2011? (N=368) 
Mean: 677.51 ± 719.48 admissions /year 
Median:550 admissions/year 
 
Of all neonates hospitalized at your 
primary institution’s NICU during 
2011, what percentage would you 
estimate were premature? (GA <32 
weeks, BWT <1500g)  (N=332) 
Mean: 74.35% preterm/year 
Median: 35% preterm/year 
 
Of those premature neonates, what 
percentage would you estimate 
were exclusively on TPN for >72 
hours? (N=381) 
0-25%  
26-50% 
51-75% 
76-100%  
38.3 
27.6 
21.3 
13.6 
 
Carnitine Supplementation Practices:  
Table 6 reports the carnitine practices of survey respondents. This table indicates 
that on average 1-2 infants are identified on newborn screening to be deficient of 
carnitine and treated for this deficiency. Of the last four preterm neonates on 
TPN under the respondents’ care, 89% of physicians do not routinely screen for 
deficiency however 40% do give L-carnitine supplementation.  
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Table 6 
Carnitine Supplementation Practices 
Survey Question Response Percent of 
Respondents 
How many infants were identified on 
newborn screening to have carnitine 
deficiency and were treated in your NICU? 
(N=226)  
Mean: 1.61 ± 8.9 infants 
Median: 0 infants 
 
Of the last 4 PT neonates on TPN, how 
many did you evaluate for serum carnitine 
deficiency? (N=370) 
0 
1 
2 
3 
4 
89.1 
3.2 
1.4 
0.8 
5.4 
Of the last 4 PT neonates on TPN, how 
many received L-carnitine 
supplementation? (N=369) 
0 
1 
2 
3 
4 
42.0 
8.9 
7.9 
1.6 
39.6 
 
Physicians’ Beliefs on Carnitine Supplementation: 
The respondents’ thoughts on carnitine are outlined in Table 7. Most respondents 
use carnitine supplemented TPN; 67% of neonatologists correctly identified 
carnitine as present in breast milk; that a deficiency in carnitine may have serious 
consequences in preterm infants (60%); and that the benefits of carnitine are not 
controversial. 17.9% of the respondents agree to the possibility of carnitine 
having side effects, 21% were aware of placental secretion. 98% believed that 
carnitine could be neuroprotective and 72% believed that carnitine deficiency 
was not a rare event in PT. The respondents would give an average dosage of 
20 mg/kg/day to preterm infants.  
Table 7 
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Physicians’ Beliefs on Carnitine Supplementation 
Survey Question Response Percent of 
Respondents 
Use carnitine supplemented TPN (N=341) Agree 65.1 
Benefits of Carnitine are Controversial 
(N=341) 
Agree 42.2 
Possible Side Effects of Carnitine(N=341) Agree 17.9 
Carnitine is present in breast 
milk/formula(N=339) 
Agree 67.3 
Carnitine is secreted by the placenta 
(N=335) 
Agree 20.9 
Carnitine may be neuroprotective (N=336) Agree 44.3 
Carnitine deficiency is rare in PT infants on 
TPN (N=337) 
Agree 28.5 
Carnitine deficiency may have serious 
consequences in PT infants (N=337) 
Agree 59.9 
Dose of carnitine they would give Mean: 19.88 ± 35.31 mg/kg/day 
Median: 10 mg/kg/day  
 
 Compared To Last Survey: 
While the responses to both surveys come from a different sample, some 
frequencies are compared. There were fewer attendings that responded but of 
those attendings that did respond, a similar proportion had more than 10 years of 
experience and spent a similar amount of time in the NICU. There was an 
increase in the number of NICU admissions and in the percentage of preterm 
births. There is no change in the proportion of respondents who believe that a 
carnitine deficiency is not rare, but there have been increases in the proportion of 
respondents who believe that carnitine is present in breast milk, secreted by the 
placenta and that a deficiency can cause serious consequences in preterm 
infants.  
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Table 8 
 
Comparison of 2001 and 2012 Survey Respondent Demographics  
 
 2001 2012 
Respondents Attendings: 95% 
>10 years experience: 65% 
Mean weeks/year in NICU: 31 
Attendings: 87.5% 
>10 years experience: 63.4% 
Mean weeks/year in NICU: 29.49 
Hospital NICU admissions: 560 
Pre-term: 63% 
 
NICU admissions: 677.51 
Pre-term: 74.35%  
 
 
 
 
Figure 3: Comparison of 2001 and 2012 Survey Results. This bar graph illustrates the responses 
obtained in 2001’s and 2012’s Carnitine survey.  
 
Selected Response Comparison: 
 
Doctors in Level III NICUs are only slightly more likely to screen neonates for 
carnitine deficiency or give them carnitine supplementation. Doctors with more 
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than 5 years of experience are more likely to screen for deficiency or supplement 
carnitine.  
Table 9 
Selected Responses Compared by Level of NICU and Years of Experience 
Question Percent of Respondents 
Neonates were not 
screened for deficiency 
Level I: 100% 
Level II: 100% 
Level III: 88.3% 
<5 years experience: 97.3% 
5-10 years experience: 82% 
>10 years experience: 87.9% 
Neonates did not receive L-
carnitine supplementation 
Level I: 75% 
Level II: 58% 
Level III: 40.3% 
<5 years experience: 49.3% 
5-10 years experience: 40% 
>10 years experience: 41.6% 
 
As shown in Figure 4, there was no significant difference between the doses 
doctors would give at a Level I, II or III NICU (pLevel I and II= n.s, pLevel I and III= n.s 
and pLevel II and III= n.s). 
 
Figure 4: Theoretical Dosage of Carnitine to Administer. This bar graph illustrates the doses 
respondents from Levels I,II and III NICUs would administer.  
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Once again, Figure 5 shows that there was no significant difference in the 
dose of carnitine they would administer (p>10years and <5 years= n.s, p>10years and 5-10 
years= n.s and p5-10 years and <5 years= n.s).  
 
Figure 5: Comparison of Carnitine Dosage and Years of Experience. This bar graph illustrates the 
average dose of carnitine physicians with decreasing years of experience would administer.  
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DISCUSSION 
 
Our findings:  
Premature neonates continue to be at risk for carnitine deficiency. 
Carnitine supplementation practices have slightly increased in the past decade 
but a large proportion of premature neonates are not routinely supplemented 
carnitine. This survey demonstrated that there continues to be significant 
variability in the supplementation practices. With respect to the hypotheses 
initially set forth, there is no majority regarding carnitine supplementation as 40% 
do use carnitine supplemented TPN and 42% do not. Interestingly, while 2/3 of 
the neonatologists are aware of the role of carnitine in preterm nutrition since it is 
present in breast milk, almost 90% of neonatologists do not screen for carnitine 
deficiencies.  
Remarkably, many neonatologists (79%) are not aware that carnitine is 
secreted by the placenta. Previously, it was thought that fetal carnitine came from 
the mother in transplacental transfer; however, a study in 2006, found the 
enzyme involved in the last step of carnitine biosynthesis in the placenta 
suggesting that when maternal carnitine supply is limited, the fetal-placental unit 
may supply carnitine for metabolism (Oey et al., 2006).  
Our results appear to be in agreement with a similar survey that examined 
nutritional practices in NICUs in 2006. While this survey examined the specific 
doses of protein and lipid supplementation and their respective rates of 
advancement, they found that a larger proportion of dieticians than physicians 
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added carnitine (p=0.042) and 65% of respondents added carnitine to their TPN 
for LBW infants (Hans, Pylipow, Long, Thureen, & Georgieff, 2009).  
Individualized Nutrition and Carnitine Recommendations:  
In keeping with the National Institute of Child Health and Human 
Development’s goal of providing “optimal nutrition that meets the unique and 
changing nutrient requirements of ELBW infants and mimics normal fetal growth” 
(Hay et al., 1999) it is important that physicians start considering carnitine 
supplementation as opposed to disregarding it given its role in fetal and infant 
nutrition.  Similarly, the survey administered by Hans et al. (2009)  found that 
clinicians are initiating parenteral and enteral nutrition earlier in life at larger 
volumes which suggests a customization of nutrition to meet the specific needs 
of the infant (Hans et al., 2009).   
A study compared the effects of computerizing the composition of 
parenteral solutions. They found that optimizing early parenteral nutrition specific 
to the individual neonate improves the nutrient content and early postnatal 
outcomes (Eleni-dit-Trolli et al., 2009).  Furthermore, Tan et al. (2008) found that 
improving early energy deficit using a hyperalimented (macronutrients above the 
current recommendation) feeding regimen may promote brain growth in very 
preterm infants (Tan, Abernethy, & Cooke, 2008).  
While these studies do not discuss the role or dose of carnitine, Crill et al 
(2007) recommend initiating carnitine supplementation on neonates that are 
expected to be on parenteral nutrition for 7 or more days at a dose between 10-
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20 mg/kg/day in an IV or oral form. Carnitine therapy should be considered in 
neonates receiving parenteral nutrition with IV fat emulsion intolerance, 
increased triglycerides and patients with short bowel syndrome, diffuse 
inflammatory bowel disease, or malabsorption that causes the neonate to receive 
caloric intake via parenteral nutrition (Crill & Helms, 2007).  
Lastly, the value of carnitine screening in both the infant and mother 
cannot be denied. Schimmenti et al. (2007) report a significant cohort of patients 
with fatty acid oxidation disorders remain asymptomatic until adulthood and carry 
a lifetime risk of sudden death; these disorders can present with low levels of 
carnitine. Therefore, it is crucial to test both the infant and the mother in the event 
of low newborn carnitine screening levels (Schimmenti et al., 2007).  
Sample Representativeness:  
It is reasonable to conclude that our sample was representative in light of 
studies reporting that surveys with lower response rates, near 20%, produce 
more accurate response rates than surveys with response rates of 60-70% 
(Visser, Krosnick, Marquette, & Curtin, 1996). Also, Holbrook et al. (2005) 
examined the results of 81 national surveys with varying response rates (5-54%) 
and they found that surveys with lower response rates were only minimally less 
accurate with respect to representativeness (Holbrook, Krosnick, & Pfent, 2007).  
Furthermore, the survey on nutritional practices in the NICU conducted in 
2006; much like our survey, had a response rate of 23% (n=775); but unlike our 
survey 70% of their respondents were physicians (Hans et al., 2009). 
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Carnitine and its Side Effects:  
As previously mentioned there was a great amount of variability in 
carnitine practices. Further examination reveals that this may be due to 20% of 
respondents who believe that carnitine may have possible side effects. A large 
proportion (42%) believes the benefits of carnitine are controversial and 56% that 
do not think carnitine may be neuroprotective.  
Indeed, the manufacturer in L-carnitine supplements has a label that 
warns patients of an increased risk for seizure activity in patients who may or 
may not have underlying seizure disorders (Crill & Helms, 2007). The first four 
weeks of life have a higher incidence of seizures than any other time of life 
(“Neonatal Seizures,” 2012). Although the incidence has not been established, it 
is estimated to occur in 80-120 cases per 100,000 neonates per year (“Neonatal 
Seizures,” 2012). Seizures in neonates are caused by: hypoxic-ischemic 
encephalopathy; intracranial, subarachnoid, germinal matrix-intraventricular and 
subdural hemorrhages; metabolic disorders such as hypoglycemia and 
hypocalcemia; and intracranial infections (“Neonatal Seizures,” 2012). 
Specifically, the manufacturers of L-carnitine had received 13 reports of seizure 
occurrence.   
In adult literature reports, other reported side effects of mild 
gastrointestinal symptoms such as gastritis, vomiting, diarrhea and abdominal 
cramping have been reported (Weschler, Aviram, Levin, Better, & Brook, 1984). 
However, these side effects are dose dependent and dose manipulation with 
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either dilution or slow consumption may alleviate these undesired effects. When 
uremic patients who suffer from renal insufficiency were treated with carnitine 
and there was transient elevation of triglycerides and increased platelet 
aggregation which could predispose them to thromboembolic phenomena. 
Thromboembolism is the formation of a clot in a blood vessel that can dislodge 
itself in other blood vessels in the brain, heart or lungs and result in severe 
damage (Weschler et al., 1984).  
There is also a theoretical risk of reduced closure of the patent ductus 
arteriosus (PDA) in infants receiving carnitine supplementation and being treated 
with indomethacin (Seidner et al., 2001). Indomethacin is used in treatment of 
PDA closure in neonates as it enhances the process of apoptosis (Seidner et al., 
2001). Carnitine is known to reduce apoptosis in models of ischemia-reperfusion 
injury (Pande et al., 2005). In our previous study, an increase in PDA ligation, a 
corrective surgical process, was observed in infants treated with indomethacin 
(Pande et al., 2005). However, this may have occurred because those infants 
had a lower birthweight and had received more fluids prior to intervention (Pande 
et al., 2005). Increased fluid intake has been associated with failure of medical 
management of PDA which may have been the cause of PDA ligation (Pande et 
al., 2005).  
Controversies Regarding Carnitine Supplementation Dosage:  
Response variability can be attributed to current controversies regarding 
carnitine supplementation doses. Theoretical doses of carnitine much higher than 
 35 
the recommended doses were observed in our survey. For example, the average 
dose of all respondents was 19.88 ± 35.31 mg/kg/day and there was no 
significant difference between respondents from Level I, II, or III NICU’s nor was 
there a difference between neonatologists with less than 5 years, 5-10 years and 
more than 10 years of experience. The recommended dose of carnitine in 
neonates is 10 mg/kg/day and higher doses may have negatives effects. For 
example, Sulkers et al. (1990) used a dose of 48 mg/kg/day of carnitine and they 
reported decreased nitrogen balance and weight gain.  
In a longitudinal retrospective drug utilization review of indication 
prescription, administration of L-carnitine was justified and appropriate in 18% of 
patients (Gómez-Oliván, Valdés-Alanis, Castro-Pastrana, Galar-Martinez, & 
Romero-Castillo, 2011). Prescriptions were considered “appropriate” when no 
errors were found regarding pharmacotherapeutic variables such as indication, 
dosage regimen, dose adjustment for nutritional status, contraindications and 
drug interactions (Gómez-Oliván et al., 2011). However, the choice to consider 
carnitine was appropriate in 86.9% of prescriptions but 60.7% of the prescriptions 
had doses that were outside of the recommended doses (Gómez-Oliván et al., 
2011).   
Limitations:  
There are some limitations to the data presented in this survey. Firstly, the 
physicians in this survey are not all board certified which means that our 
respondents may have been a mixed sample of residents, students, foreign 
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fellows and other medical profession. Next, there is an inherent bias of 
respondents who completed the survey, it is likely that they may have had an 
interest in carnitine supplementation and may have been knowledgeable on the 
subject. There is also a recall bias where physicians treating many premature 
neonates may report carnitine screening and supplementation more often than 
physicians that do not encounter as many premature neonates. Lastly, the data 
reported in this survey reflects the intention of the respondents with respect to 
providing nutrition to LBW infants but the data does not confirm nor reflect the 
actual screening and supplementation practices.   
Conclusion:  
Our national survey indicates that premature neonates in the US do not 
routinely receive carnitine supplementation during the perinatal period. Two-
thirds of respondents recognized carnitine presence in breast milk, but 4/5 did 
not identify placental secretion. Neonatologists believed that carnitine deficiency 
was not rare in PT, with potential serious consequences. Almost all believed that 
carnitine could be neuroprotective (98%). Yet, few respondents routinely 
screened for deficiency (5%) or used supplemented TPN (40%), leaving most 
premature neonates still at risk for unrecognized carnitine deficiency and its 
serious consequences.  
Future Directions:  
Given the significant impact that prematurity has on the health and 
development of our children and the substantial health care costs attributable to 
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the morbidities associated with prematurity, it is imperative that we develop better 
strategies to improve developmental outcomes in this patient population.  Thus, it 
is important from both a public health and scientific standpoint to follow the L-
carnitine supplementation randomized clinical trial to determine if it has an impact 
on this outcome.  Improvement in neurodevelopmental outcomes in extremely 
preterm infants following carnitine supplementation has the potential to challenge 
current nutritional recommendations for this very vulnerable population.  
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APPENDIX 
Survey:  
The purpose of this survey is to gather information about the carnitine 
supplementation practices of neonatologists. You are invited to complete this 
anonymous online survey, which should take approximately 5 minutes to 
complete. 
 
1. CONSENT: You must choose a response in order to continue with the survey. 
TPN Supplementation Study 
I voluntarily consent to participate in this study 
I wish to read more about informed consent in this study 
I do not wish to participate in this study 
Full Informed Consent Information  
 
BACKGROUND 
The purpose of this survey is to gather information about the carnitine 
supplementation practices of neonatologists. 
 
STUDY PROCEDURE 
You are invited to complete this anonymous online survey, which should take 
approximately 5 minutes to complete. 
 
RISKS 
There are no foreseeable risks for participating in this study. 
 
BENEFITS 
There is no direct benefit for participation in this study. However, you may benefit 
from participating by having the opportunity to consider and share information 
regarding carnitine supplementation practices. 
 
CONFIDENTIALITY 
Data will be kept confidential. Email or url addresses will not be connected to any 
of the research data, ensuring the privacy of individual data. In publications, data 
will be presented in unidentifiable and aggregate forms. 
 
CONTACT 
If you have any questions, complaints or concerns about this study, you can 
contact Dr. Marie Clark at 7188397025 or by email at mclark@montefiore.org. 
Institutional Review Board: Contact the Institutional Review Board (IRB) if you 
have questions regarding your rights as a research participant. Also, contact the 
IRB if you have questions, complaints or concerns which you do not feel you can 
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discuss with the investigator. The Albert Einstein College of Medicine IRB may 
be reached by phone at (718) 7980406. 
 
VOLUNTARY PARTICIPATION 
It is up to you to decide whether to take part in this study. Refusal to participate 
or the decision to withdraw from this research will involve no penalty or loss of 
benefits to which you are otherwise entitled. This will not affect your relationship 
with the investigator. 
 
COSTS AND COMPENSATION TO PARTICIPANTS 
The only cost for you is the time it takes to complete this survey. There will be no 
compensation for participating in this study. 
 
2. By clicking on the link below, you confirm that you have read the information in 
this consent form and agree to voluntarily participate in this study. 
I agree to participate in this study. 
I do not wish to participate in this study. 
 
3. Are you currently in active practice (on average >20 hours/week)?  
Yes  
No 
 
4. Do you currently spend at least 8 weeks/year in a neonatal intensive care unit 
(NICU)?  
Yes 
No 
 
5. Please indicate your current position in Neonatology:  
Attending 
Fellow 
NP/PA 
Other (please specify): ______________________ 
 
6. Since completion of your residency training, how many years have you spent 
in the field of Neonatology? (or if non-MD, how many years since completion of 
schooling?) 
<2 years 
2-5 years 
>5-10 years 
>10 years 
 
7. How many weeks/year are you responsible for direct patient care or direct 
supervision of care in your NICU?  
NICU weeks/year ___________________ 
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8. Please choose the level of the NICU in which you spend most of your time.  
I 
II 
III 
 
Please describe your patient population.  
 
9. How many newborn infants were hospitalized in your NICU during 2011 (Jan-
Dec):  
NICU admissions/year __________________ 
 
10. Of all neonates hospitalized at your primary institution’s NICU during 2011, 
what percentage would you estimate were premature (PT: GA<32 weeks, 
BWT<1500g)?  
% PT/year _________________ 
 
11. Of those premature neonates, what percentage would you estimate were 
exclusively on TPN for >72 hours?  
0-25% 
26-50% 
51-75% 
76-100% 
 
12. Does your state have an expanded newborn screen that identifies carnitine 
deficiency?  
Yes  
No 
I don’t know 
 
13. How many infants were identified on newborn screening to have carnitine 
deficiency and were treated in your NICU? 
# infants identified and treated ______________ 
 
14. Of the last 4 premature neonates exclusively on TPN under your direct 
care/supervision, how many did you evaluate for serum carnitine deficiency?  
0 
1 
2 
3 
4 
 
15. Of the last 4 premature neonates exclusively on TPN under your direct 
care/supervision, how many received L-carnitine supplementation?  
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0 
1 
2 
3 
4 
 
Please describe your current practices.  
 
16. Please indicate if you agree or disagree with the following statements 
regarding L-carnitine supplementation in PT infants.  
 
 Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
I use carnitine supplemented 
TPN. 
     
There is an established 
carnitine dose used in our 
NICU.  
     
Benefits of supplementation 
remain controversial.  
     
There are possible side 
effects.  
     
Carnitine is present in breast 
milk and infant formula. 
     
Carnitine is secreted by the 
placenta. 
     
Carnitine may be neuro-
protective.  
     
 
17. What dose of carnitine would you use in a preterm infant?  
mg/kg/day __________ 
 
18. Please indicate if you agree or disagree with the following statements 
regarding L-carnitine deficiency in premature neonates:  
 Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
Screening for deficiency is 
expensive.  
     
Carnitine deficiency is rare in 
PT infants on TPN.   
     
Deficiency may have serious 
consequences in PT infants.   
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Raw Data Tables:  
Table 10 
 
Full Respondent Characteristics.  
 
Survey Question Response Percent of 
Respondents 
Are you currently on active practice 
(on average >20 hours/week)? 
(N=474) 
Yes 
No  
97.25 
2.75 
Do you currently spend at least 8 
weeks/year in a neonatal intensive 
care unit (NICU)? (N=473) 
Yes 
No 
96.62 
3.38 
 
Please indicate your current 
position in Neonatology: (N=465) 
 
Attending 
Fellow  
NP/PA 
Nutrition Manager/Dietician 
Professor 
Retired 
Pediatrician Level I Nursery 
87.5 
10.1 
2.4 
1.0 
0.2 
0.2 
0.2 
Since completion of your residency 
training, how many years have you 
spent in Neonatology? (N=473) 
>10 years 
>5-10 years 
2-5 years 
<2 years 
63.4 
13.5 
13.7 
9.3 
How many weeks/year are you 
responsible for direct patient 
care/supervision in NICU? (N=470)  
Mean: 29.49 ± 16.64 weeks/year 
Median: 26 weeks 
Mode: 52 weeks  
 
Table 11 
 
Full Hospital’s Carnitine Screening and Dosing Practices  
Survey Question Response Percent of 
Respondents 
Please choose the level of NICU 
in which you spend most of your 
time. (N=473) 
Level I 
Level II 
Level III 
1.3 
6.9 
91.8 
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Does your state have an 
expanded screen for carnitine 
deficiency? (N=385) 
Yes 
No 
I don’t know 
6.9 
9.6 
24.4 
Screening for deficiency is not 
easily available (N=344) 
Disagree 
Neutral 
Agree 
41.6 
30.2 
26.5 
Screening for deficiency is 
expensive (N=344) 
Disagree 
Neutral 
Agree 
26.4 
52.3 
19.5 
How many newborn infants were 
hospitalized in your NICU during 
2011? (N=368) 
Mean: 677.51 ± 719.48 admissions/year 
Median:550 admissions/year 
Mode: 500 admissions/year 
Of all neonates hospitalized at 
your primary institution’s NICU 
during 2011, what percentage 
would you estimate were 
premature? (GA <32 weeks, BWT 
<1500g)  (N=332) 
Mean: 74.35% ± 366.3 preterm/year 
Median: 35% preterm/year 
Mode: 30% preterm/year 
Hospital has an established dose 
of carnitine. (N=341)  
Disagree 
Neutral 
Agree 
26.1 
37 
21.5 
 
Table 12 
 
Full NICU Population Characteristics 
 
Survey Question Response Percent of 
Respondents 
Of those premature neonates, what 
percentage would you estimate were 
exclusively on TPN for >72 hours? 
(N=381) 
0-25%  
26-50% 
51-75% 
76-100%  
38.3 
27.6 
21.3 
13.6 
How many infants were identified on 
newborn screening to have carnitine 
deficiency and were treated in your NICU? 
(N=226)  
Mean: 1.61 ± 8.9 infants 
Median: 0 infants 
Mode: 0 infants 
Of the last 4 PT neonates on TPN, how 
many did you evaluate for serum carnitine 
deficiency? (N=370) 
0 
1 
2 
3 
4 
89.1 
3.2 
1.4 
0.8 
5.4 
Of the last 4 PT neonates on TPN, how 
many received L-carnitine 
0 
1 
42.0 
8.9 
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supplementation? (N=369) 2 
3 
4 
7.9 
1.6 
39.6 
 
Table 13 
Full Physicians’ Beliefs on Carnitine Supplementation 
Survey Question Response Percent of 
Respondents 
Use carnitine supplemented TPN 
(N=341) 
Disagree 
Neutral 
Agree 
21.7 
13.2 
65.1 
Benefits of Carnitine are Controversial 
(N=341) 
Disagree 
Neutral 
Agree 
16.1 
41.6 
42.2 
Possible Side Effects of 
Carnitine(N=341) 
Disagree 
Neutral 
Agree 
24.3 
57.8 
17.9 
Carnitine is present in breast 
milk/formula(N=339) 
Disagree 
Neutral 
Agree 
4.1 
28.6 
67.3 
Carnitine is secreted by the placenta 
(N=335) 
Disagree 
Neutral 
Agree 
5.7 
73.4 
20.9 
Carnitine may be neuroprotective 
(N=336) 
Disagree 
Neutral 
Agree 
2.4 
53.3 
44.3 
Carnitine deficiency is rare in PT infants 
on TPN (N=337) 
Disagree 
Neutral 
Agree 
31.2 
40.4 
28.5 
Carnitine deficiency may have serious 
consequences in PT infants (N=337) 
Disagree 
Neutral 
Agree 
4.2 
35.9 
59.9 
Dose of carnitine they would give Mean: 19.88 ± 35.31 mg/kg/day 
Median: 10 mg/kg/day  
Mode: 10 mg/kg/day 
  
Table 14 
 
Full Comparison of 2001 and 2012 Survey Respondent Demographics  
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 2001 2012 
Respondents Attendings: 95% 
>10 years experience: 65% 
Mean weeks/year in NICU: 31 
Attendings: 87.5% 
>10 years experience: 63.4% 
Mean weeks/year in NICU: 29.49 
Hospital NICU admissions: 560 
Pre-term: 63% 
Exclusively on TPN: 46% 
Screened for deficiency: 2%  
Routinely received carnitine 
supplemented TPN: 28% 
NICU admissions: 677.51 
Pre-term: 74.35%  
Exclusively on TPN: ?? 
Screened for deficiency: 5.4%  
Routinely received carnitine 
supplemented TPN: 39.6% 
Knowledge Deficiency is not rare: 34% 
Present in breast milk: 52% 
Secreted by placenta: 12% 
Deficiency can cause serious 
consequences: 34% 
Deficiency is not rare: 31% 
Present in breast milk: 66% 
Secreted by placenta: 21% 
Deficiency can cause serious 
consequences: 59% 
 
 
Table 15 
 
Full Comparison of Selected Responses from Level I, II, III NICUs 
 
 Level I:  Level II: Level III: 
What percentage 
would you 
estimate were 
exclusively on 
TPN for >72 
hours?  
0-25: 20% 
26-50: 20% 
51-75: 40% 
76-100: 20% 
N=5 
0-25: 68% 
26-50: 9% 
51-75: 13% 
76-100: 9% 
N=22 
0-25: 36.5% 
26-50: 28.4% 
51-75: 21.3% 
76-100: 13.8% 
N=356 
Neonates 
evaluated for 
serum  carnitine 
deficiency 
0: 100%  
1: 0% 
2: 0% 
3: 0% 
4: 0% 
N=4 
0: 100% 
1: 0% 
2: 0% 
3: 0% 
4: 0% 
N=24 
0: 88.3% 
1: 3.5% 
2: 1.5% 
3: 0.9% 
4: 5.9% 
N=341 
Received L-
carnitine 
supplementation 
0: 75% 
1: 0% 
2: 0% 
3: 0% 
4: 25% 
N=4 
0: 58% 
1: 0% 
2: 0% 
3: 8% 
4: 33% 
N=24 
0: 40.3% 
1: 9.7% 
2: 16.8% 
3: 1.2% 
4: 40.3% 
N=340 
Dose of carnitine 
they would give 
6.75 ± 3.94 
mg/kg/day 
N= 160 
11.83 ± 5.42 
mg/kg/day 
N=29 
20.91 ± 36.67 
mg/kg/day 
N=40 
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Table 16 
 
Full Comparison of Selected Responses by Years of Experience 
 
 More than 10 
years 
5-10 years Less than 5 years 
% Exclusively on 
TPN for >72 
hours? 
0-25: 41.6% 
26-50: 26.3% 
51-75: 18.7% 
76-100: 13.3% 
N= 262 
0-25: 65.6% 
26-50: 43.8% 
51-75: 31.3% 
76-100: 18.8% 
N=32 
0-25: 22.5% 
26-50: 30.9% 
51-75: 30.9% 
76-100: 15.5% 
N=71 
Infants identified 
and treated for 
carnitine 
deficiency 
1.95 ± 12.89  3.23 ± 7.86 0.25 ± 0.5 
Neonates 
evaluated for 
serum  carnitine 
deficiency 
0: 87.9%  
1: 4.0% 
2: 1.6% 
3: 0.8% 
4: 5.7% 
N=247 
0: 82% 
1: 4% 
2: 2% 
3: 0% 
4: 12% 
N=50 
0: 97.3% 
1: 0% 
2: 0% 
3: 1.4% 
4: 1.4% 
N=73 
Received L-
carnitine 
supplementation 
0: 41.6% 
1: 8.6% 
2: 8.1% 
3: 0.8% 
4: 40.8% 
N=245 
0: 40% 
1: 10% 
2: 10% 
3: 6% 
4: 34% 
N=50 
0: 49.3% 
1: 7% 
2: 4% 
3: 1% 
4: 38% 
N=71 
Dose of carnitine 
they would give 
20.35 ± 38.70 
mg/kg/day 
N= 160 
18.51 ± 13.41 
mg/kg/day 
N=29 
19.2 ± 32.39 
mg/kg/day 
N=40 
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